Dynamics of a large extra dimension inspired hybrid inflation model

In low scale quantum gravity scenarios the fundamental scale of nature can be as low as TeV, in order to address the naturalness of the electroweak scale. A number of difficulties arise in constructing specific models; stabilisation of the radius of the extra dimensions, avoidance of overproduction of Kaluza Klein modes, achieving successful baryogenesis and production of a close to scale-invariant spectrum of density perturbations with the correct amplitude. We examine in detail the dynamics, including radion stabilisation, of a hybrid inflation model that has been proposed in order to address these difficulties, where the inflaton is a gauge singlet residing in the bulk. We find that for a low fundamental scale the phase transition, which in standard four dimensional hybrid models usually ends inflation, is slow and there is second phase of inflation lasting for a large number of e-foldings. The density perturbations on cosmologically interesting scales exit the Hubble radius during this second phase of inflation, and we find that their amplitude is far smaller than is required. We find that the duration of the second phase of inflation can be short, so that cosmologically interesting scales exit the Hubble radius prior to the phase transition, and the density perturbations have the correct amplitude, only if the fundamental scale takes an intermediate value. Finally we comment briefly on the implications of an intermediate fundamental scale for the production of primordial black holes and baryogenesis.Comment: 9 pages, 2 figures version to appear in Phys. Rev. D, additional references and minor changes to discussio

Current-induced highly dissipative domains in high Tc thin films

We have investigated the resistive response of high Tc thin films submitted to a high density of current. For this purpose, current pulses were applied into bridges made of Nd(1.15)Ba(1.85)Cu3O7 and Bi2Sr2CaCu2O8. By recording the time dependent voltage, we observe that at a certain critical current j*, a highly dissipative domain develops somewhere along the bridge. The successive formation of these domains produces stepped I-V characteristics. We present evidences that these domains are not regions with a temperature above Tc, as for hot spots. In fact this phenomenon appears to be analog to the nucleation of phase-slip centers observed in conventional superconductors near Tc, but here in contrast they appear in a wide temperature range. Under some conditions, these domains will propagate and destroy the superconductivity within the whole sample. We have measured the temperature dependence of j* and found a similar behavior in the two investigated compounds. This temperature dependence is just the one expected for the depairing current, but the amplitude is about 100 times smaller.Comment: 9 pages, 9 figures, Revtex, to appear in Phys. Rev.

Bose-Einstein condensates in a one-dimensional double square well: Analytical solutions of the Nonlinear Schr\"odinger equation and tunneling splittings

We present a representative set of analytic stationary state solutions of the Nonlinear Schr\"odinger equation for a symmetric double square well potential for both attractive and repulsive nonlinearity. In addition to the usual symmetry preserving even and odd states, nonlinearity introduces quite exotic symmetry breaking solutions - among them are trains of solitons with different number and sizes of density lumps in the two wells. We use the symmetry breaking localized solutions to form macroscopic quantum superpositions states and explore a simple model for the exponentially small tunneling splitting.Comment: 11 pages, 11 figures, revised version, typos and references correcte

One-dimension cubic-quintic Gross-Pitaevskii equation in Bose-Einstein condensates in a trap potential

By means of new general variational method we report a direct solution for the quintic self-focusing nonlinearity and cubic-quintic 1D Gross Pitaeskii equation (GPE) in a harmonic confined potential. We explore the influence of the 3D transversal motion generating a quintic nonlinear term on the ideal 1D pure cigar-like shape model for the attractive and repulsive atom-atom interaction in Bose Einstein condensates (BEC). Also, we offer a closed analytical expression for the evaluation of the error produced when solely the cubic nonlinear GPE is considered for the description of 1D BEC.Comment: 6 pages, 3 figure

Bianchi {VI}0_{0} in Scalar and Scalar-Tensor Cosmologies

We study several cosmological models with Bianchi \textrm{VI}$_{0}$ symmetries under the self-similar approach. In order to study how the \textquotedblleft constants\textquotedblright\ $G$ and $\Lambda$ may vary, we propose three scenarios where such constants are considered as time functions. The first model is a perfect fluid. We find that the behavior of $G$ and $\Lambda$ are related. If $G$ behaves as a growing time function then $\Lambda$ is a positive decreasing time function but if $G$ is decreasing then $\Lambda$ is negative. For this model we have found a new solution. The second model is a scalar field, where in a phenomenological way, we consider a modification of the Klein-Gordon equation in order to take into account the variation of $G$. Our third scenario is a scalar-tensor model. We find three solutions for this models where $G$ is growing, constant or decreasing and $\Lambda$ is a positive decreasing function or vanishes. We put special emphasis on calculating the curvature invariants in order to see if the solutions isotropize.Comment: Typos corrected. References added, minor corrections. arXiv admin note: text overlap with arXiv:0905.247

The Dynamics of Brane-World Cosmological Models

Brane-world cosmology is motivated by recent developments in string/M-theory and offers a new perspective on the hierarchy problem. In the brane-world scenario, our Universe is a four-dimensional subspace or {\em brane} embedded in a higher-dimensional {\em bulk} spacetime. Ordinary matter fields are confined to the brane while the gravitational field can also propagate in the bulk, leading to modifications of Einstein's theory of general relativity at high energies. In particular, the Randall-Sundrum-type models are self-consistent and simple and allow for an investigation of the essential non-linear gravitational dynamics. The governing field equations induced on the brane differ from the general relativistic equations in that there are nonlocal effects from the free gravitational field in the bulk, transmitted via the projection of the bulk Weyl tensor, and the local quadratic energy-momentum corrections, which are significant in the high-energy regime close to the initial singularity. In this review we discuss the asymptotic dynamical evolution of spatially homogeneous brane-world cosmological models containing both a perfect fluid and a scalar field close to the initial singularity. Using dynamical systems techniques it is found that, for models with a physically relevant equation of state, an isotropic singularity is a past-attractor in all orthogonal spatially homogeneous models (including Bianchi type IX models). In addition, we describe the dynamics in a class of inhomogeneous brane-world models, and show that these models also have an isotropic initial singularity. These results provide support for the conjecture that typically the initial cosmological singularity is isotropic in brane-world cosmology.Comment: Einstein Centennial Review Article: to appear in CJ

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials